Tag - ARQL

ArQule (NASDAQ:ARQL) dosed the first patient in its MOSAIC trial evaluating miransertib for the treatment of Proteus syndrome (PS) and phosphoinositide 3 kinase (PIK3CA)-related overgrowth spectrum disorders (PROS).  PS...